Stock Analysis on Net

Illumina Inc. (NASDAQ:ILMN)

This company has been moved to the archive! The financial data has not been updated since November 5, 2021.

Analysis of Profitability Ratios 
Quarterly Data

Microsoft Excel

Profitability Ratios (Summary)

Illumina Inc., profitability ratios (quarterly data)

Microsoft Excel
Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Return on Sales
Gross profit margin 69.30% 68.63% 67.61% 68.01% 69.02% 70.34% 70.36% 69.63% 69.24% 68.84% 69.06% 69.01% 69.44% 68.85% 67.98% 66.35% 65.68% 66.26% 67.53% 69.48%
Operating profit margin -0.75% 17.02% 16.82% 17.91% 22.08% 25.69% 27.28% 27.80% 26.42% 24.88% 25.58% 26.49% 28.25% 27.58% 26.29% 22.02% 20.01% 20.06% 21.35% 24.48%
Net profit margin 21.17% 19.36% 18.14% 20.25% 19.70% 20.68% 26.49% 28.28% 28.13% 27.55% 25.05% 24.78% 21.09% 20.88% 19.31% 26.38% 30.14% 30.07% 30.52% 19.29%
Return on Investment
Return on equity (ROE) 8.55% 14.83% 12.80% 13.98% 13.57% 15.19% 20.32% 21.72% 21.92% 21.65% 21.36% 21.98% 19.53% 19.90% 18.85% 26.41% 27.38% 27.54% 29.01% 21.06%
Return on assets (ROA) 6.01% 8.85% 7.20% 8.65% 8.62% 9.56% 12.97% 13.70% 13.73% 13.45% 11.52% 11.87% 10.12% 11.08% 10.23% 13.81% 15.49% 15.39% 16.10% 10.81%

Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Illumina Inc. gross profit margin ratio improved from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021.
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Illumina Inc. operating profit margin ratio improved from Q1 2021 to Q2 2021 but then deteriorated significantly from Q2 2021 to Q3 2021.
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Illumina Inc. net profit margin ratio improved from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Illumina Inc. ROE improved from Q1 2021 to Q2 2021 but then deteriorated significantly from Q2 2021 to Q3 2021.
ROA A profitability ratio calculated as net income divided by total assets. Illumina Inc. ROA improved from Q1 2021 to Q2 2021 but then deteriorated significantly from Q2 2021 to Q3 2021.

Gross Profit Margin

Illumina Inc., gross profit margin calculation (quarterly data)

Microsoft Excel
Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Selected Financial Data (US$ in millions)
Gross profit 770 802 764 630 526 428 619 662 648 573 584 590 597 575 538 542 482 434 368 419 426 424 397
Revenue 1,108 1,126 1,093 953 794 633 859 952 907 838 846 868 853 830 782 778 714 662 598 619 607 600 572
Profitability Ratio
Gross profit margin1 69.30% 68.63% 67.61% 68.01% 69.02% 70.34% 70.36% 69.63% 69.24% 68.84% 69.06% 69.01% 69.44% 68.85% 67.98% 66.35% 65.68% 66.26% 67.53% 69.48%
Benchmarks
Gross Profit Margin, Competitors2
AbbVie Inc. 67.72% 65.62% 64.82% 66.41% 68.74% 73.56% 77.43% 77.64%
Amgen Inc. 74.00% 73.97% 74.37% 74.59% 75.55% 77.15% 78.90% 80.38%
Bristol-Myers Squibb Co. 76.92% 75.88% 74.42% 72.31% 71.18% 69.47% 68.02% 69.10%
Danaher Corp. 60.44% 59.24% 57.60% 55.98% 55.04% 55.28% 55.85% 55.74%
Eli Lilly & Co. 74.85% 74.27% 75.88% 77.66% 78.26% 78.67% 79.22% 78.85%
Gilead Sciences Inc. 80.23% 79.90% 80.32% 81.23% 78.72% 78.25% 79.06% 78.86%
Johnson & Johnson 67.51% 67.00% 66.24% 65.58% 65.68% 65.66% 66.15% 66.42%
Merck & Co. Inc. 67.95% 67.48% 66.99% 67.74% 71.23% 70.06% 70.11% 69.87%
Moderna Inc. 84.71% 84.49% 89.60% 96.03%
Pfizer Inc. 65.28% 70.96% 76.46% 79.26% 80.47% 80.19% 80.03% 80.25%
Regeneron Pharmaceuticals Inc. 86.65% 86.85% 86.84% 86.82% 87.98% 88.21% 89.72% 90.05%
Thermo Fisher Scientific Inc. 51.05% 51.29% 51.47% 49.67% 47.31% 45.39% 44.30% 44.35%

Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).

1 Q3 2021 Calculation
Gross profit margin = 100 × (Gross profitQ3 2021 + Gross profitQ2 2021 + Gross profitQ1 2021 + Gross profitQ4 2020) ÷ (RevenueQ3 2021 + RevenueQ2 2021 + RevenueQ1 2021 + RevenueQ4 2020)
= 100 × (770 + 802 + 764 + 630) ÷ (1,108 + 1,126 + 1,093 + 953) = 69.30%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Gross profit margin Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. Illumina Inc. gross profit margin ratio improved from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021.

Operating Profit Margin

Illumina Inc., operating profit margin calculation (quarterly data)

Microsoft Excel
Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Selected Financial Data (US$ in millions)
Income (loss) from operations (545) 187 193 133 162 96 189 268 308 205 204 197 241 227 218 230 181 143 52 143 161 162 121
Revenue 1,108 1,126 1,093 953 794 633 859 952 907 838 846 868 853 830 782 778 714 662 598 619 607 600 572
Profitability Ratio
Operating profit margin1 -0.75% 17.02% 16.82% 17.91% 22.08% 25.69% 27.28% 27.80% 26.42% 24.88% 25.58% 26.49% 28.25% 27.58% 26.29% 22.02% 20.01% 20.06% 21.35% 24.48%
Benchmarks
Operating Profit Margin, Competitors2
AbbVie Inc. 30.09% 28.95% 23.63% 24.81% 28.45% 30.17% 39.86% 39.03%
Amgen Inc. 30.14% 30.72% 37.23% 37.70% 38.59% 39.76% 41.89% 43.57%
Bristol-Myers Squibb Co. -15.73% -17.02% -19.19% -21.60% 9.27% 11.67% 16.30% 22.62%
Danaher Corp. 24.63% 25.04% 22.30% 18.99% 17.61% 17.37% 18.01% 18.25%
Eli Lilly & Co. 23.17% 21.81% 22.06% 24.69% 23.55% 24.48% 25.64% 22.29%
Gilead Sciences Inc. 42.79% 37.20% 18.07% 16.72% 11.01% -4.40% 19.89% 19.38%
Johnson & Johnson 24.69% 25.23% 24.10% 23.60% 24.30% 24.64% 25.62% 24.15%
Merck & Co. Inc. 14.07% 10.64% 14.02% 16.47% 26.87% 25.40% 25.49% 24.77%
Moderna Inc. 69.57% 62.28% 32.79% -381.82%
Pfizer Inc. 24.67% 24.12% 21.20% 19.47% 21.17% 21.17% 24.20% 25.46%
Regeneron Pharmaceuticals Inc. 55.19% 53.94% 43.37% 42.09% 37.43% 34.64% 30.45% 28.10%
Thermo Fisher Scientific Inc. 27.04% 28.00% 27.68% 24.19% 20.90% 17.05% 17.86% 17.99%

Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).

1 Q3 2021 Calculation
Operating profit margin = 100 × (Income (loss) from operationsQ3 2021 + Income (loss) from operationsQ2 2021 + Income (loss) from operationsQ1 2021 + Income (loss) from operationsQ4 2020) ÷ (RevenueQ3 2021 + RevenueQ2 2021 + RevenueQ1 2021 + RevenueQ4 2020)
= 100 × (-545 + 187 + 193 + 133) ÷ (1,108 + 1,126 + 1,093 + 953) = -0.75%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Operating profit margin A profitability ratio calculated as operating income divided by revenue. Illumina Inc. operating profit margin ratio improved from Q1 2021 to Q2 2021 but then deteriorated significantly from Q2 2021 to Q3 2021.

Net Profit Margin

Illumina Inc., net profit margin calculation (quarterly data)

Microsoft Excel
Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Selected Financial Data (US$ in millions)
Net income attributable to Illumina stockholders 317 185 147 257 179 47 173 239 234 296 233 210 199 209 208 68 163 128 367 124 129 120 90
Revenue 1,108 1,126 1,093 953 794 633 859 952 907 838 846 868 853 830 782 778 714 662 598 619 607 600 572
Profitability Ratio
Net profit margin1 21.17% 19.36% 18.14% 20.25% 19.70% 20.68% 26.49% 28.28% 28.13% 27.55% 25.05% 24.78% 21.09% 20.88% 19.31% 26.38% 30.14% 30.07% 30.52% 19.29%
Benchmarks
Net Profit Margin, Competitors2
AbbVie Inc. 13.66% 12.40% 10.28% 10.08% 18.16% 19.20% 24.77% 23.69%
Amgen Inc. 23.03% 23.80% 29.60% 29.97% 30.91% 31.53% 33.64% 35.32%
Bristol-Myers Squibb Co. -11.89% -11.44% -14.53% -21.20% -0.11% -1.61% 3.08% 13.15%
Danaher Corp. 20.97% 21.00% 19.17% 16.36% 18.05% 18.35% 18.13% 16.80%
Eli Lilly & Co. 21.52% 22.71% 23.91% 25.24% 24.01% 24.48% 23.97% 37.27%
Gilead Sciences Inc. 27.21% 19.62% 1.19% 0.51% 5.56% -1.18% 22.17% 24.35%
Johnson & Johnson 19.55% 19.92% 17.95% 17.82% 21.01% 18.86% 20.75% 18.42%
Merck & Co. Inc. 15.09% 11.83% 15.09% 14.72% 24.33% 22.20% 21.10% 21.01%
Moderna Inc. 64.55% 57.01% 30.95% -373.77%
Pfizer Inc. 28.77% 23.86% 24.03% 22.95% 18.59% 31.31% 32.32% 31.45%
Regeneron Pharmaceuticals Inc. 51.65% 50.11% 43.53% 41.35% 38.28% 37.30% 28.56% 26.91%
Thermo Fisher Scientific Inc. 21.93% 22.47% 22.08% 19.79% 17.12% 14.12% 14.31% 14.47%

Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).

1 Q3 2021 Calculation
Net profit margin = 100 × (Net income attributable to Illumina stockholdersQ3 2021 + Net income attributable to Illumina stockholdersQ2 2021 + Net income attributable to Illumina stockholdersQ1 2021 + Net income attributable to Illumina stockholdersQ4 2020) ÷ (RevenueQ3 2021 + RevenueQ2 2021 + RevenueQ1 2021 + RevenueQ4 2020)
= 100 × (317 + 185 + 147 + 257) ÷ (1,108 + 1,126 + 1,093 + 953) = 21.17%

2 Click competitor name to see calculations.

Profitability ratio Description The company
Net profit margin An indicator of profitability, calculated as net income divided by revenue. Illumina Inc. net profit margin ratio improved from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021.

Return on Equity (ROE)

Illumina Inc., ROE calculation (quarterly data)

Microsoft Excel
Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Selected Financial Data (US$ in millions)
Net income attributable to Illumina stockholders 317 185 147 257 179 47 173 239 234 296 233 210 199 209 208 68 163 128 367 124 129 120 90
Total Illumina stockholders’ equity 10,593 5,180 4,922 4,694 4,700 4,563 4,635 4,613 4,439 4,332 3,985 3,758 3,503 3,257 3,008 2,749 2,855 2,715 2,551 2,197 2,240 2,056 1,991
Profitability Ratio
ROE1 8.55% 14.83% 12.80% 13.98% 13.57% 15.19% 20.32% 21.72% 21.92% 21.65% 21.36% 21.98% 19.53% 19.90% 18.85% 26.41% 27.38% 27.54% 29.01% 21.06%
Benchmarks
ROE, Competitors2
AbbVie Inc. 55.60% 53.01% 37.63% 35.30% 48.34% 47.30%
Amgen Inc. 68.26% 69.67% 75.91% 77.20% 67.09% 68.48% 80.92% 81.07%
Bristol-Myers Squibb Co. -14.52% -13.80% -16.54% -23.84% -0.09% -1.15% 1.91% 6.66%
Danaher Corp. 13.54% 13.12% 11.76% 9.17% 9.70% 9.56% 10.53% 9.94%
Eli Lilly & Co. 76.99% 94.20% 88.31% 109.79% 115.45% 137.26% 179.72% 319.09%
Gilead Sciences Inc. 34.44% 26.20% 1.59% 0.68% 7.27% -1.43% 22.49% 23.91%
Johnson & Johnson 25.44% 25.53% 22.96% 23.25% 26.35% 24.11% 28.01% 25.42%
Merck & Co. Inc. 20.10% 16.73% 26.08% 27.91% 39.47% 37.91% 38.72% 37.99%
Moderna Inc. 69.75% 52.13% 15.59% -29.17% -21.66% -16.54% -30.82% -43.75%
Pfizer Inc. 26.28% 18.86% 16.23% 15.21% 12.22% 22.05% 24.21% 25.77%
Regeneron Pharmaceuticals Inc. 40.53% 41.02% 33.43% 31.86% 31.17% 32.94% 18.79% 19.08%
Thermo Fisher Scientific Inc. 22.13% 23.32% 22.60% 18.47% 15.33% 12.41% 12.85% 12.45%

Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).

1 Q3 2021 Calculation
ROE = 100 × (Net income attributable to Illumina stockholdersQ3 2021 + Net income attributable to Illumina stockholdersQ2 2021 + Net income attributable to Illumina stockholdersQ1 2021 + Net income attributable to Illumina stockholdersQ4 2020) ÷ Total Illumina stockholders’ equity
= 100 × (317 + 185 + 147 + 257) ÷ 10,593 = 8.55%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROE A profitability ratio calculated as net income divided by shareholders’ equity. Illumina Inc. ROE improved from Q1 2021 to Q2 2021 but then deteriorated significantly from Q2 2021 to Q3 2021.

Return on Assets (ROA)

Illumina Inc., ROA calculation (quarterly data)

Microsoft Excel
Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016
Selected Financial Data (US$ in millions)
Net income attributable to Illumina stockholders 317 185 147 257 179 47 173 239 234 296 233 210 199 209 208 68 163 128 367 124 129 120 90
Total assets 15,063 8,675 8,755 7,585 7,404 7,248 7,261 7,316 7,089 6,973 7,390 6,959 6,759 5,851 5,542 5,257 5,046 4,858 4,598 4,281 4,228 3,985 3,794
Profitability Ratio
ROA1 6.01% 8.85% 7.20% 8.65% 8.62% 9.56% 12.97% 13.70% 13.73% 13.45% 11.52% 11.87% 10.12% 11.08% 10.23% 13.81% 15.49% 15.39% 16.10% 10.81%
Benchmarks
ROA, Competitors2
AbbVie Inc. 5.06% 4.50% 3.43% 3.07% 4.93% 4.65% 9.25% 8.84%
Amgen Inc. 8.63% 9.61% 11.33% 11.54% 11.37% 11.23% 12.45% 13.13%
Bristol-Myers Squibb Co. -4.87% -4.58% -5.53% -7.61% -0.04% -0.44% 0.74% 2.65%
Danaher Corp. 7.13% 7.19% 6.30% 4.79% 5.05% 4.86% 4.74% 4.85%
Eli Lilly & Co. 12.39% 12.70% 13.01% 13.28% 12.68% 13.39% 13.46% 21.17%
Gilead Sciences Inc. 11.02% 7.59% 0.45% 0.18% 2.08% -0.46% 8.31% 8.74%
Johnson & Johnson 9.98% 10.07% 8.76% 8.41% 9.95% 9.59% 11.07% 9.59%
Merck & Co. Inc. 7.70% 6.14% 7.73% 7.72% 12.83% 11.56% 11.95% 11.66%
Moderna Inc. 33.75% 21.64% 4.71% -10.18% -12.85% -13.98% -24.46% -32.34%
Pfizer Inc. 11.10% 7.78% 7.01% 6.23% 4.46% 7.97% 9.47% 9.72%
Regeneron Pharmaceuticals Inc. 29.55% 28.88% 22.53% 20.47% 19.62% 20.68% 14.46% 14.29%
Thermo Fisher Scientific Inc. 11.64% 12.70% 12.02% 9.23% 7.62% 6.02% 6.25% 6.33%

Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-10-02), 10-Q (reporting date: 2016-07-03), 10-Q (reporting date: 2016-04-03).

1 Q3 2021 Calculation
ROA = 100 × (Net income attributable to Illumina stockholdersQ3 2021 + Net income attributable to Illumina stockholdersQ2 2021 + Net income attributable to Illumina stockholdersQ1 2021 + Net income attributable to Illumina stockholdersQ4 2020) ÷ Total assets
= 100 × (317 + 185 + 147 + 257) ÷ 15,063 = 6.01%

2 Click competitor name to see calculations.

Profitability ratio Description The company
ROA A profitability ratio calculated as net income divided by total assets. Illumina Inc. ROA improved from Q1 2021 to Q2 2021 but then deteriorated significantly from Q2 2021 to Q3 2021.